| Feature | Specification |
|---|---|
| Application | Protein Quantification |
| Sample Volume | 5 µL |
The CD32a (FcgRIIa, H131) cellular binding assay is a simple and robust test to monitor binding of the IgG Fc region to the human CD32a receptorin live cells and to select the most potent antibody for use in Antibody-Dependent Cell-Phagocytosis (ADCP). Two separate CD32a assays are available to specifically target the H131 or R131 variants. These assays, based on our innovative Tag-lite technology, can easily be automated to create a high-throughput solution for predicting ADCP.
The CD32a receptor cellular binding assay is a competitive assay involving HEK293 cells expressing a specific CD32a variant conjugated to Lumi4-terbium Cryptate, and human IgG1 labelled with d2. The unlabeled antibody or Fc tagged drug competes with the d2 labelled IgG1 for binding to the receptor, resulting in a decrease of FRET signal.
The CD32a receptor cellular binding assays (FcgIIa H131 or R131) present only 1 incubation step after reagents distribution. Lumi4-terbium Cryptate pre-labelled cells are dispensed, followed by the addition of IgG1 labelled with d2 and the sample. After 2h incubation at RT, the signal can be read.
| Application |
Protein Quantification
|
|---|---|
| Brand |
HTRF
|
| Detection Modality |
HTRF
|
| Product Group |
Kit
|
| Sample Volume |
5 µL
|
| Shipping Conditions |
Shipped in Dry Ice
|
| Target Class |
Biologics
|
| Technology |
TR-FRET
|
| Therapeutic Area |
Cardiovascular
Infectious Diseases
Metabolism/Diabetes
NASH/Fibrosis
Neuroscience
Rare Diseases
|
| Unit Size |
100 assay points
|
Are you looking for resources, click on the resource type to explore further.
Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...
We are here to answer your questions.